Hearing Aid Device Patent Landscape 2026
Hearing Aid Device Patent Landscape in 2026
The hearing aid device patent field is highly concentrated, with a small cluster of implant-focused specialists — led by MED-EL and Cochlear — commanding the majority of filings across the hundred largest applicants. The field is past its 2020 peak, with annual filing volume easing across most incumbents, though publication lag means the most recent years are still under-counted.
MED-EL and Cochlear lead a tightly held field
The top-ranked applicant, MED EL Elektromedizinische Geraete GmbH, holds 2,323 patent records, placing it clearly ahead of second-ranked Advanced Bionics AG at 1,783 patent records — a gap that reflects years of sustained investment in cochlear implant and electrotherapy IP.
The top five filers together account for 57% of the combined total across the hundred largest applicants, signaling a field where a handful of implant specialists dominate and mid-tier challengers face a substantial IP density barrier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | MED EL Elektromedizinische Geraete GmbH | 2,323 | |
| 2 | Advanced Bionics AG | 1,783 | |
| 3 | Medtronic Inc | 496 | |
| 4 | Greatbatch Ltd | 324 | |
| 5 | Advanced Bionics LLC | 307 | |
| 6 | Envoy Medical Corp | 247 | |
| 7 | Starkey Laboratories Inc | 236 | |
| 8 | Oticon | 205 | |
| 9 | Oticon Medical AS | 171 | |
| 10 | Regents of the University of California | 144 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Cardiac Pacemakers Inc | 141 | |
| 12 | University of Melbourne | 103 | |
| 13 | Boston Scientific Neuromodulation Corp | 102 | |
| 14 | Second Sight Medical Products Inc | 100 | |
| 15 | Sonova AG | 98 | |
| 16 | Acclarent Inc | 97 | |
| 17 | NewSouth Innovations Pty Ltd | 85 | |
| 18 | Cognito Therapeutics Inc | 71 | |
| 19 | Cochlear Corp | 69 | |
| 20 | University of Iowa Research Foundation | 67 |
The leaders’ positions reflect deep specialization in electrotherapy (A61N) and audio transducer (H04R) technologies, with cross-filing into implant and prosthesis classes (A61F) — a portfolio architecture that is difficult to replicate quickly and shapes freedom-to-operate for new entrants.
Filing counts for 2024 and 2025 are substantially under-counted due to the standard 18-to-24-month patent publication lag; any apparent drop in those years should not be read as a real decline in inventive activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing volume has eased from its 2020 peak; electrotherapy dominates the technology mix
The annual trend chart reveals that the field reached a peak in 2020 and has since seen easing annual volumes, while the technology composition chart shows electrotherapy as the overwhelmingly dominant branch, with audio transducers and diagnostics forming a secondary tier.
Annual filing trend
Annual filings peaked in 2020 at 789 patent records, then declined through 2022 at 605 and 2023 at 419. Counts for 2024 and 2025 are substantially incomplete due to publication lag and should not be treated as indicators of true activity levels.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy & radiation therapy) is the dominant branch by a wide margin, followed at a distance by H04R (Loudspeakers & audio transducers) and A61B (Diagnosis & surgery). Secondary branches — A61F (Implants & prostheses) and A61M (Devices for body fluids) — indicate meaningful activity in device engineering and fluid management, while branches such as G16H (Healthcare informatics) and G06N (AI-based computing) remain comparatively sparse.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Method, apparatus, and computer program for adjust…
The present disclosure relates to a concept for adjusting a hearing aid device. A sound pattern is provided to a person wearing the hearing aid device configured according to current hearing aid settings. The person’s pupils are evaluated to obtain pupillary information in response to the sound pattern perceived via the hearing aid device. The current… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Cochlear implant system component having multiple … | 1,445 |
| 2 | Method and apparatus for surgical navigation | 1,232 |
| 3 | Magnetically shielded assembly | 1,126 |
| 4 | Techniques for data retention upon detection of an… | 1,033 |
| 5 | Gateway platform for biological monitoring and del… | 1,025 |
| 6 | Cochlear implant system for an auditory prosthesis | 996 |
| 7 | Implantable device with improved battery rechargin… | 983 |
| 8 | Method and apparatus for surgical navigation | 891 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment
Four structural observations shape where new investment is most — and least — likely to find clear IP space: the field’s lifecycle stage, the degree of concentration, the collaboration ecosystem, and the geographic footprint.
Past-peak field with easing annual volume since 2020
The lifecycle stage is classified as Decline, driven by annual filings easing back from the 2020 peak of 789 patent records. This does not necessarily indicate shrinking commercial interest, but it does suggest that the core cochlear implant and electrotherapy IP space is maturing. New entrants should expect high prior-art density in dominant branches and prioritize differentiated claims in adjacent technology areas.
Past-peak · 2020 highTop five control 57% of the hundred largest filers’ combined total
The field is heavily concentrated: MED-EL (2,323 patent records), Advanced Bionics AG (1,783), Medtronic (496), Greatbatch (324), and Advanced Bionics LLC (307) together hold 57% of the patent records among the top 100 applicants. The gap between the top two and the rest is wide enough that mid-tier players would require sustained, focused filing programs to close it. University and research-institute entrants — including the University of Melbourne and the Regents of the University of California — are visible but well below the commercial leaders.
High concentrationCochlear and Oticon Medical anchor the most active co-filing pairs
The most prolific collaboration pair is Cochlear Limited and Oticon Medical AS, with 54 co-filed patent records — an unusually high count that suggests a structured joint-development arrangement. Cochlear also co-files extensively with the University of Melbourne (21 records) and with the University of Zurich (8 records), reflecting a sustained academic partnership model. MED-EL co-files with Cornell University (14 records), the University of Salamanca (8 records), and Johns Hopkins University (8 records), showing a parallel strategy of distributed academic collaboration.
Ecosystem co-filingUS and EPO dominate; Asia-Pacific coverage is limited
The United States is by far the primary filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). Australia ranks fourth — consistent with Cochlear’s home market — and Germany fifth. China, Canada, and India appear at lower volumes, and Asian markets such as Japan, South Korea, and Taiwan have comparatively thin coverage, which may represent either a deliberate portfolio choice by incumbents or an underserved entry point for regionally focused competitors.
US-led · thin AsiaGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Cochlear Limited | Oticon Medical AS | 54 |
| Cochlear Limited | University of Melbourne | 21 |
| Advanced Bionics LLC | Alfred E. Mann Foundation for Scientific Research | 15 |
| MED EL Elektromedizinische Geraete GmbH | Cornell University | 14 |
| Cochlear Limited | UNIVERSITY OF LAS PALMAS DE GRAN CANARIA | 12 |
| Oticon Medical AS | University College London | 10 |
| Cochlear Limited | University of Zurich | 8 |
| MED EL Elektromedizinische Geraete GmbH | University of Salamanca | 8 |
| MED EL Elektromedizinische Geraete GmbH | Johns Hopkins University | 8 |
| Oticon Medical AS | Oticon | 7 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
MED-EL and Cochlear lead; most incumbents show declining momentum
The two largest filers share nearly identical technology profiles centered on electrotherapy and audio transducers, but differ in trajectory: Cochlear is declining more gradually while MED-EL has seen a steeper recent drop. Advanced Bionics LLC stands out as a new entrant in recent filing activity.
MED EL Elektromedizinische Geraete GmbH
The corpus leader at 2,323 patent records, MED-EL concentrates its portfolio in A61N 1 (electrotherapy), H04R 25 (audio transducers), and A61F 11 (implants and prostheses) — the canonical cochlear-implant technology stack. Recent momentum shows a 56% decline versus the prior period, consistent with the field-wide post-2020 easing, though the absolute portfolio size remains the largest in the corpus.
patent records: 2,323Cochlear Limited
Cochlear is the most active recent filer at 398 patent records in the recent window, with a comparatively moderate decline of 13% versus the prior period — the shallowest drop among the measured incumbents. Its technology focus mirrors MED-EL’s (A61N 1, H04R 25, A61F 11), and it is the anchor of the field’s most active collaboration network, co-filing with Oticon Medical AS, the University of Melbourne, and the University of Zurich.
patent records: recent 398| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Cochlear Limited | 398 | ▼ -13% |
| MED EL Elektromedizinische Geraete GmbH | 42 | ▼ -56% |
| Advanced Bionics AG | 43 | ▼ -80% |
| Advanced Bionics LLC | 33 | ▲ new entrant |
| Medtronic Inc | 6 | ▼ -62% |
| Oticon Medical AS | 25 | ▼ -83% |
| Greatbatch Ltd | 12 | ▼ -54% |
| Envoy Medical Corp | 72 | ▼ -11% |
Under-served branches adjacent to the core implant stack
Several IPC branches appear at comparatively low share relative to the dominant A61N cluster; two stand out for their plausible technical relevance to hearing aid devices and realistic entry paths for differentiated filers.
G16H · Healthcare Informatics
With 415 patent records and only 1% share of the branch distribution, G16H is sparse relative to the core electrotherapy cluster despite clear relevance to remote monitoring, fitting software, and patient-data platforms for implantable hearing devices. Envoy Medical Corp is an early mover here (21 records in G16H 40), but the branch remains open. An entry path exists for software-forward players or platform companies with existing digital-health infrastructure, targeting patient management and audiologist-facing analytics.
Search this in Eureka →G06N · AI-Based Computing
G06N holds only 122 patent records — roughly 1% of the total branch distribution — despite machine-learning techniques being directly applicable to signal processing, noise cancellation, and personalized fitting in both implantable and conventional hearing aids. The sparsity likely reflects a lag between commercial deployment of AI features and corresponding patent filings. Players with AI or audio-ML capabilities could file foundational claims in this branch without immediately competing against the dense A61N prior-art landscape held by MED-EL and Cochlear.
Search this in Eureka →How leading applicants differ across technology routes
Strength of each leader across the main technology routes.
| Player | A61N 1 · Electrotherapy & radiation therapy | H04R 25 · Loudspeakers & audio transducers | A61B 5 · Diagnosis & surgery | A61F 11 · Implants & prostheses | A61F 2 · Implants & prostheses |
|---|---|---|---|---|---|
| Cochlear Limited | Strong · 2,199 | Moderate · 854 | Emerging · 350 | Moderate · 648 | Emerging · 415 |
| MED EL Elektromedizinische Geraete GmbH | Strong · 2,119 | Moderate · 557 | Emerging · 268 | Emerging · 391 | Emerging · 149 |
| Advanced Bionics AG | Strong · 1,395 | Moderate · 435 | Emerging · 150 | Emerging · 25 | Absent |
| Advanced Bionics LLC | Strong · 568 | Emerging · 96 | Absent | Emerging · 87 | Emerging · 28 |
| Oticon Medical AS | Strong · 381 | Moderate · 157 | Emerging · 55 | Absent | Absent |
| Medtronic Inc | Strong · 431 | Absent | Emerging · 86 | Absent | Absent |
| Envoy Medical Corp | Strong · 240 | Moderate · 97 | Absent | Absent | Emerging · 19 |
Frequently asked questions
The corpus contains 5,079 patent families in scope. Separately, patent-record counts (which can exceed the family total because a family may be filed across multiple jurisdictions) are used for applicant rankings and branch tallies.
MED EL Elektromedizinische Geraete GmbH holds the top position with 2,323 patent records, followed by Advanced Bionics AG at 1,783 patent records. Both companies concentrate their portfolios in electrotherapy (A61N 1), audio transducers (H04R 25), and implant/prosthesis classes (A61F 11).
No. Annual filing volume peaked in 2020 at 789 patent records and has eased since, placing the field in a past-peak (Decline) lifecycle stage. The most recent years (2024–2025) show very low counts, but those figures are substantially incomplete due to the standard 18-to-24-month publication lag and should not be taken as the final tally for those years.
The United States leads with 6,171 patent records, followed by Europe (EPO) at 2,837 and WIPO (PCT) at 1,855. Australia ranks fourth at 1,134 — consistent with Cochlear’s home market — and Germany fifth at 847. Asian markets including China (393), Japan (113), and South Korea (42) have comparatively thin coverage.
Cochlear Limited and Oticon Medical AS are the most active co-filing pair with 54 co-filed records. Cochlear also collaborates with the University of Melbourne (21 records) and the University of Zurich (8 records). MED-EL co-files with Cornell University (14 records), the University of Salamanca (8 records), and Johns Hopkins University (8 records).
Healthcare informatics (G16H, 415 records, 1% share) and AI-based computing (G06N, 122 records) are the most notable under-served branches relative to the dominant electrotherapy core. Both have direct technical relevance — patient data platforms and ML-driven signal processing, respectively — but remain sparsely filed, suggesting room for differentiated claims by software-forward or AI-focused entrants.
Map your own hearing aid device patent landscape
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.